Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura-Maria Krabbe

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
International Journal of Molecular Sciences|September 13, 2016
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate CancerKatrin Schlack, Laura-Maria Krabbe, Manfred Fobker, et al.
Translational Andrology and Urology|October 28, 2016
Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?Yvonne Klaile, Katrin Schlack, Martin Boegemann, et al.
Clinical Genitourinary Cancer|August 17, 2024
Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint InhibitorsMatteo Silberg, Laura-Maria Krabbe, Martin Bögemann, et al.
The Journal of Urology|May 27, 2014
Prospective external validation of a bladder cancer detection modelYair Lotan, Robert S Svatek, Laura-Maria Krabbe, et al.
Translational Andrology and Urology|November 22, 2021
ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysisKatrin Schlack, Laura-Maria Krabbe, Kambiz Rahbar, et al.
Deutsches Arzteblatt International|August 1, 2022
The Treatment of Metastatic, Hormone-Sensitive Prostatic CarcinomaAxel S Merseburger, Laura-Maria Krabbe, Bernd Joachim Krause, et al.
World Journal of Urology|June 28, 2018
Molecularly-driven precision medicine for advanced bladder cancerLaura-Maria Krabbe, Vitaly Margulis, Andres Jan Schrader, et al.
The Cochrane Database of Systematic Reviews|May 10, 2017
Partial nephrectomy versus radical nephrectomy for clinical localised renal massesFrank Kunath, Stefanie Schmidt, Laura-Maria Krabbe, et al.
Cancers|October 28, 2023
Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology ImagesOkyaz Eminaga, Sami-Ramzi Leyh-Bannurah, Shahrokh F Shariat, et al.
Oncotarget|September 7, 2019
A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy settingMartin Boegemann, Katrin Schlack, Lena Früchtenicht, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
International Journal of Molecular Sciences|September 13, 2016
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate CancerKatrin Schlack, Laura-Maria Krabbe, Manfred Fobker, et al.
Translational Andrology and Urology|October 28, 2016
Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?Yvonne Klaile, Katrin Schlack, Martin Boegemann, et al.
Clinical Genitourinary Cancer|August 17, 2024
Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint InhibitorsMatteo Silberg, Laura-Maria Krabbe, Martin Bögemann, et al.
The Journal of Urology|May 27, 2014
Prospective external validation of a bladder cancer detection modelYair Lotan, Robert S Svatek, Laura-Maria Krabbe, et al.
Translational Andrology and Urology|November 22, 2021
ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysisKatrin Schlack, Laura-Maria Krabbe, Kambiz Rahbar, et al.
Deutsches Arzteblatt International|August 1, 2022
The Treatment of Metastatic, Hormone-Sensitive Prostatic CarcinomaAxel S Merseburger, Laura-Maria Krabbe, Bernd Joachim Krause, et al.
World Journal of Urology|June 28, 2018
Molecularly-driven precision medicine for advanced bladder cancerLaura-Maria Krabbe, Vitaly Margulis, Andres Jan Schrader, et al.
The Cochrane Database of Systematic Reviews|May 10, 2017
Partial nephrectomy versus radical nephrectomy for clinical localised renal massesFrank Kunath, Stefanie Schmidt, Laura-Maria Krabbe, et al.
Cancers|October 28, 2023
Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology ImagesOkyaz Eminaga, Sami-Ramzi Leyh-Bannurah, Shahrokh F Shariat, et al.
Oncotarget|September 7, 2019
A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy settingMartin Boegemann, Katrin Schlack, Lena Früchtenicht, et al.
Pageof 10